
    
      This is a single arm open-labeled neoadjuvant phase II clinical trial evaluating everolimus
      in combination with an aromatase inhibitor in postmenopausal women with hormone receptor
      positive/HER2 negative breast cancers with low and intermediate risk (< 25) Recurrence Scores
      by Oncotype Dx.
    
  